Burney Co. Acquires 4,079 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Burney Co. boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,840 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,079 shares during the period. Burney Co.’s holdings in Jazz Pharmaceuticals were worth $2,936,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JAZZ. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the period. Venturi Wealth Management LLC boosted its position in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after acquiring an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,253 shares of company stock valued at $1,001,434. Corporate insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Piper Sandler reissued an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Trading Up 0.2 %

NASDAQ:JAZZ opened at $123.24 on Thursday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.04 and a beta of 0.56. The company’s 50 day moving average price is $122.76 and its 200-day moving average price is $114.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.